Unibest

Pharmaceutical intermediates

Lotilaner Intermediates

3 pharmaceutical intermediates for Lotilaner. Indication: Demodectic Blepharitis.

提交项目All intermediates

About Lotilaner

Originator
Elanco Tiergesundheit Ag
Indication
Demodectic Blepharitis
Approved Date
07/24/2023
NCE Patent
07/24/2028
DS/DP
01/17/2030

Available intermediates

3 intermediates currently listed for Lotilaner. Request specifications, documentation or a quotation for any item below.

Lotilaner intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
2-bromo-3-methyl-5-acetylthiophene859199-06-7//
methyl 5-acetyl-3-methylthiophene-2-carboxylate2758907-87-6//
5-acetyl-3-methyl-2-Thiophenecarboxylic acid2758907-91-2//

Other programs under L

(LCZ696)LanifibranorLapatinibLarotrectinibLasmiditanLazertinib MesylateLemborexantLenacapavir sodium

Building toward Lotilaner?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →